logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
J

Joseph Ciccolini

Centre de Recherche en Cancérologie de Marseille

42H-index
415Paper Count
6.4KCitation Count
Published Papers 114
Publication Date
logo
Correction to: The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer
errCancer Chemotherapy and Pharmacology
IF2.3
err2026-07-18
err0
PREAI
errClémence Marin; Anthéa Deschamps; Quentin Gerbault; Clémence Toullec; Florian Clatot; Maureen Bernadach; Jérôme Fayette; Amaury Daste; Philippe Ceruse; Mickael Burgy; Cédric Champetier; Cyril Abdeddaim; Esma Saada-Bouzid; Xavier Tchiknavorian; Sylvie Zanetta; Pascal Auquier; Joseph Ciccolini; Sébastien Salas
errShare
errSave
The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer
errCancer Chemotherapy and Pharmacology
IF2.3
err2026-04-29
err0
PREAI
errAnthéa Deschamps; Clémence Marin; Quentin Gerbault; Clémence Toullec; Florian Clatot; Maureen Bernadach; Jérôme Fayette; Amaury Daste; Philippe Ceruse; Mickael Burgy; Cédric Champetier; Cyril Abdeddaim; Esma Saada-Bouzid; Xavier Tchiknavorian; Sylvie Zanetta; Pascal Auquier; Joseph Ciccolini; Sébastien Salas
errShare
errSave
Bringing 5-FU monitoring home: microsampling as the potential next step beyond DPD deficiency screening
errExpert Opinion on Drug Metabolism & Toxicology
IF3.4
err2026-01-01
err0
PREAI
errLaunay, Manon; Schmitt, Antonin; Ciccolini, Joseph
errShare
errSave
Predicting the toxicity-efficacy ratio of venetoclax in real-world patients
errAnnals of Hematology
IF2.4
err2025-12-11
err0
errOAAI
errLoïc Osanno; Lucy Brocque; Laurent Bourguignon; Carla Delpech; Laure Farnault; Julien Colle; Pauline Roche; Jacques Chiaroni; Caroline Izard; Régis Costello; Mathilde Dacos; Caroline Solas; Chems Djezzar; Joseph Ciccolini; Thomas Cluzeau; Geoffroy Venton; Raphaëlle Fanciullino
errShare
errSave
Eco Friendly and Budget Smart: An Economic and Environmental Evaluation of Alternative PD-1 and PD-L1 Inhibitor Dosing Regimens
errPharmacoEconomics
IF4.6
err2025-09-10
err0
errOAAI
errLeo Karlsson; Joseph Ciccolini; Rob ter Heine; Maddalena Centanni
errShare
errSave
Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High-Risk MDS Treated With Nucleoside Analogs
errHEMATOLOGICAL ONCOLOGY
IF3.9
err2025-03-01
err0
PREAI
errCollomb, Erwann; Bourguignon, Laurent; Tichadou, Antoine; Roche, Pauline; Berton, Guillaume; Ciccolini, Joseph; Colle, Julien; Farnault, Laure; Costello, Regis; Fanciullino, Raphaelle; Venton, Geoffroy
errShare
errSave
Adaptive dosing of high-dose busulfan in real-world adult patients undergoing haematopoietic cell transplant conditioning
errBRITISH JOURNAL OF CLINICAL PHARMACOLOGY
IF3
err2024-11-20
err0
errOAAI
errProtzenko, Dorian; Bouchacourt, Benjamin; Carriat, Laure; Maroselli, Paul; Boeri, Clara; Devillier, Raynier; Ciccolini, Joseph
errShare
errSave
PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errCiccolini, J.; Hamimed, M.; Marolleau, S.; Perez, C.; Benzekry, S.; Le Ray, M.; Boyer, A.; Audigier-Valette, C.; Martinez, S.; Pegliasco, H.; Ray, P.; Falchero, L.; Serre, A.; Cloarec, N.; Lebas, L.; Hominal, S.; Mazieres, J.; Perol, M.; Greillier, L.; Barlesi, F.
errShare
errSave
Tyrosine kinase inhibitors in cancers: Treatment optimization - Part II
errCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
IF5.6
err2024-08-01
err1
PREAI
errFerrer, Florent; Tetu, Pauline; Dousset, Lea; Lebbe, Celeste; Ciccolini, Joseph; Combarel, David; Meyer, Nicolas; Paci, Angelo; Bouchet, Stephane
errShare
errSave
Tyrosine kinase inhibitors in cancers: Treatment optimization - Part I
errCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
IF5.6
err2024-07-01
err2
PREAI
errCombarel, David; Dousset, Lea; Bouchet, Stephane; Ferrer, Florent; Tetu, Pauline; Lebbe, Celeste; Ciccolini, Joseph; Meyer, Nicolas; Paci, Angelo
errShare
errSave
Pegylated liposome encapsulating docetaxel using microfluidic mixing technique: Process optimization and results in breast cancer models
errINTERNATIONAL JOURNAL OF PHARMACEUTICS
IF5.2
err2024-05-01
err2
errOAAI
errDacos, Mathilde; Immordino, Benoit; Diroff, Erwan; Sicard, Guillaume; Kosta, Artemis; Rodallec, Anne; Giacometti, Sarah; Ciccolini, Joseph; Fanciullino, Raphaelle
errShare
errSave
Animal pharmacokinetics of an anti-Her2+immunoliposome of docetaxel
errCANCER RESEARCH
IF16.6
err2024-03-22
err0
PREAI
errDacos, Mathilde; Diroff, Erwan; Giacometti, Sarah; Ciccolini, Joseph; Fanciullino, Raphaelle
errShare
errSave
Killing a fly with a sledgehammer: standard flat-dosing administration of Atezolizumab leads to marked overexposure in real-world lung cancer patients
errCANCER RESEARCH
IF16.6
err2024-03-22
err0
PREAI
errMarolleau, Sophie; Mogenet, Alice; Hamimed, Mourad; Boeri, Clara; Greillier, Laurent; Ciccolini, Joseph
errShare
errSave
Optimizing the efficacy of anti-VEGF/cytotoxics/anti-PD-1 scheduling in a lung cancer mice model through B and T cells monitoring
errCANCER RESEARCH
IF16.6
err2024-03-22
err0
PREAI
errSicard, Guillaume; Protzenko, Dorian; Giacometti, Sarah; Fanciullino, Raphaelle; Barlesi, Fabrice; Ciccolini, Joseph
errShare
errSave
Killing a fly with a sledgehammer: Atezolizumab exposure in real-world lung cancer patients
errCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY
IF3
err2023-11-27
err2
errOAAI
errMarolleau, Sophie; Mogenet, Alice; Boeri, Clara; Hamimed, Mourad; Ciccolini, Joseph; Greillier, Laurent
errShare
errSave
Immune check points in cancer treatment: current challenges and perspectives
errBRITISH JOURNAL OF CANCER
IF6.8
err2023-10-28
err4
errOAAI
errCiccolini, Joseph; Milano, Gerard
errShare
errSave
Harnessing tumor immunity with cytotoxics: T cells monitoring in mice bearing lung tumors treated with anti-VEGF and pemetrexed-cisplatin doublet
errBRITISH JOURNAL OF CANCER
IF6.8
err2023-07-31
err4
PREAI
errSicard, G.; Protzenko, D.; Giacometti, S.; Barlesi, F.; Ciccolini, J.; Fanciullino, R.
errShare
errSave
Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping
errESMO OPEN
IF8.3
err2023-06-01
err3
errOAAI
errRoyer, B.; Launay, M.; Ciccolini, J.; Derain, L.; Parant, F.; Thomas, F.; Guitton, J.
errShare
errSave
A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study
errBMC CANCER
IF3.4
err2023-05-02
err6
errOAAI
errGravis, Gwenaelle; Marino, Patricia; Olive, Daniel; Penault-LLorca, Frederique; Delord, Jean-Pierre; Simon, Clotilde; Lamrani-Ghaouti, Assia; Sabatier, Renaud; Ciccolini, Joseph; Boher, Jean-Marie
errShare
errSave
Pemetrexedcisplatin-bevacizumab combo in lung cancer models: impact on tumor immunity
errCANCER RESEARCH
IF16.6
err2023-04-04
err0
PREAI
errSicard, Guillaume; Giacometti, Sarah; Barlesi, Fabrice; Fanciullino, Raphaelle; Ciccolini, Joseph
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
É
Éric Vivier
H-index: 124 · Papers: 692
M
Matthias Schwab
H-index: 122 · Papers: 1.4K
J
Jan H.M. Schellens
H-index: 111 · Papers: 1.2K
G
Godefridus J. Peters
H-index: 103 · Papers: 1.4K
F
Fabrice Barlési
H-index: 99 · Papers: 1.5K
View more